Development of a self-assembling protein nanoparticle vaccine targeting Plasmodium falciparum Circumsporozoite Protein delivered in three Army Liposome Formulation adjuvants

2017/03/07 by Labdhi Seth, Karen M. Bingham Ferlez, Stephen A. Kaba +9 · 23 citations
Biochemistry, Genetics and Molecular Biology · Environmental Science · Medicine · #Bacteriophages and microbial interactions #Biochemistry #Biology #Circumsporozoite protein #Immunology #Liposome #Malaria #Malaria Research and Control #Medicine #Plasmodium falciparum #Virology #vaccines and immunoinformatics approaches

paper · doi:10.1016/j.vaccine.2017.02.040

openalex publication_date 2017/03/07 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/28

Abstract

We have developed FMP014, a vaccine candidate against Plasmodium falciparum malaria, which is comprised of 60 identical monomer protein chains that form an icosahedral shaped self-assembling protein nanoparticle (SAPN). Each monomer contains selected P. falciparum Circumsporozoite Protein (P f CSP) CD4+ and CD8+ epitopes, universal T H epitopes, portions of the α-TSR domain, and 6 repeats of the NANP motifs of the P f CSP. Here we describe the conditions that are required for successful scale-up and cGMP manufacturing of FMP014 with a yield of ≈1.5 g of drug substance per 100 g of wet bacterial paste. When adjuvanted with an Army Liposomal Formulation (ALF) based adjuvant, the nanoparticle vaccine is highly immunogenic and prevents infection of mice by an otherwise lethal dose of transgenic P. berghei sporozoites expressing the full-length P f CSP.

Cited by

• Introduction. [europepmc]
• Protein-protein conjugate nanoparticles for malaria antigen delivery and enhanced immunogenicity. [europepmc]
• Immune response to antigen adsorbed to aluminum hydroxide particles: Effects of co-adsorption of ALF or ALFQ adjuvant to the aluminum-antigen complex. [europepmc]
• A comprehensive model for assessment of liver stage therapies targeting Plasmodium vivax and Plasmodium falciparum. [europepmc]
• Identification of Immune Signatures of Novel Adjuvant Formulations Using Machine Learning. [europepmc]
• Application of built-in adjuvants for epitope-based vaccines. [europepmc]
• Enhanced Immunogenicity and Protective Efficacy of a Campylobacter jejuni Conjugate Vaccine Coadministered with Liposomes Containing Monophosphoryl Lipid A and QS-21. [europepmc]
• Recent Advances in Nanovaccines Using Biomimetic Immunomodulatory Materials. [europepmc]
• Plasmodium falciparum pre-erythrocytic stage vaccine development. [europepmc]
• Identification of Plasmodium falciparum circumsporozoite protein-specific CD8+ T cell epitopes in a malaria exposed population. [europepmc]
• Army Liposome Formulation (ALF) family of vaccine adjuvants. [europepmc]
• Advancements in prophylactic and therapeutic nanovaccines. [europepmc]
• Engineering and characterization of a novel Self Assembling Protein for Toxoplasma peptide vaccine in HLA-A*11:01, HLA-A*02:01 and HLA-B*07:02 transgenic mice. [europepmc]
• Carbohydrate Immune Adjuvants in Subunit Vaccines. [europepmc]
• Orientation of Antigen Display on Self-Assembling Protein Nanoparticles Influences Immunogenicity. [europepmc]
• Liposomes for malaria management: the evolution from 1980 to 2020. [europepmc]
• Novel malaria vaccines. [europepmc]
• Innovative vaccine platforms against infectious diseases: Under the scope of the COVID-19 pandemic. [europepmc]
• Design and development of a self-assembling protein nanoparticle displaying PfHAP2 antigenic determinants recognized by natural acquired antibodies. [europepmc]
• New-age vaccine adjuvants, their development, and future perspective. [europepmc]
• Malaria therapeutics: are we close enough? [europepmc]
• Accelerated prime-and-trap vaccine regimen in mice using repRNA-based CSP malaria vaccine. [europepmc]
• Antigen Delivery Platforms for Next-Generation Coronavirus Vaccines. [europepmc]

Related

• Structure-guided design of a PfCyRPA-based vaccine against blood-stage malaria
• Development of a metabolically active, non-replicating sporozoite vaccine to preventPlasmodium falciparummalaria
• A Multivalent Peptide Vaccine Against Malaria, Targeting Plasmodium Circumsporozoite Protein and Mosquito AgTRIO
• STING-adjuvanted outer membrane vesicle nanoparticle vaccine against Pseudomonas aeruginosa
• A Modular Design of a Cholera Toxin B Subunit‐Scaffolded Sub‐Virion Nanoparticle Vaccine Against West Nile Virus